donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
01521 Frontage Holdings Corporation
3.130
-0.010-0.32%
YOY
Do not show
Hide blank lines
(Q3)2022/03/31(FY)2021/12/31(Q6)2021/06/30(FY)2020/12/31
Per Share IndicaTor
Operating Cash Flow Per Share
-- -- 40.58% 0.1694 32.02% 0.047 65.82% 0.1205
Cash Flow Per Share
-- -- -2499.58% -0.2602 -563.25% -0.1129 -98.54% 0.0108
Operating Income Per Share
-- 0.2267 46.44% 0.7011 66.39% 0.3222 22.92% 0.4788
Net Asset Per Share
-- -- 10.98% 1.2159 12.76% 1.173 6.74% 1.0955
Basic Earning Per Share
-- -- 6.5% 0.0702 95.79% 0.0334 -17.04% 0.0659
Diluted  Earning Per Share
-- -- 5.43% 0.0678 100.34% 0.0326 -16.54% 0.0643
Profitability
Gross Profit Ratio
-- -- 9.67% 36.164% 20.58% 34.844% -11.21% 32.974%
Operating Profit Ratio
-- -- -13.47% 14.984% 18.84% 14.896% -19.01% 17.316%
Net Profit Ratio
-- -- -25.89% 10.259% 20.96% 10.642% -24.59% 13.842%
Earning Before Tax Ratio
-- -- -12.42% 13.590% 29.01% 13.474% -25.32% 15.517%
ROE
-- -- -1.83% 6.082% 80.91% 2.958% -48.14% 6.195%
ROA
-- -- -12.3% 4.317% 67.9% 2.242% -47.47% 4.922%
Yield Quality
Operating Profit To Total Profits
-- -- -1.2% 110.253% -7.89% 110.549% 8.44% 111.597%
Tax To Total Profits
-- -- -127.1% -24.511% -33.35% -21.020% 7.37% -10.793%
Operating Cash To Total Revenue
-- -- -4% 24.154% -20.65% 14.595% 34.9% 25.160%
Capital Structure
Debt Assets Ratio
-- -- 33.74% 32.103% 17.98% 23.851% 51.38% 24.004%
Equity Multipler
-- -- 12.67% 1.4877 4.91% 1.3185 10.82% 1.3204
Debt Equity Ratio
-- -- 49.69% 47.281% 23.61% 31.322% 67.61% 31.586%
Current Assets To tatal Assets
-- -- -33.72% 44.357% -18.46% 59.576% -12.96% 66.924%
Non Current Assets To Total Assets
-- -- 68.23% 55.643% 50.05% 40.424% 43.12% 33.076%
Current Liabilities To tatal Liabilities
-- -- -3.85% 47.783% 8.58% 49.969% -14.55% 49.699%
Non Current Liabilities To Total Liabilities
-- -- 3.81% 52.217% -7.31% 50.031% 20.23% 50.301%
Solvency
Current Ratio
-- -- -48.45% 2.8916 -36.34% 4.9987 -32.71% 5.6098
Quick Ratio
-- -- -48.54% 2.8787 -36.52% 4.9812 -32.86% 5.5939
Operating Profit To Current Liabilities
-- -- -21.19% 0.3786 30.48% 0.2604 -34.94% 0.4804
Operrating Cash Flow To Current Liabilities
-- -- -12.57% 0.6103 -12.88% 0.2551 8.37% 0.698
Share Equity Without Minority Interest To Total Liabilities
-- -- -33.64% 2.0938 -19.21% 3.1799 -40.39% 3.155
Operating Cash Flow To Total Liabilities
-- -- -15.94% 0.2916 -5.4% 0.1275 -7.4% 0.3469
Operating Profit To Total Liabilities
-- -- -24.23% 0.1809 41.67% 0.1301 -44.41% 0.2388
Operating Capacity
Current Assets Turnover(T)
-- -- 57.32% 0.795 66.69% 0.3422 -27.82% 0.5054
Fixed Assets Turnover(T)
-- -- -21.87% 2.7754 -7.29% 1.5793 -9.3% 3.5524
Total Assets Turnover(T)
-- -- 19.66% 0.4321 40.46% 0.216 -29.3% 0.3611
Growth Ability
Operating Revenue GR 3Y
-- -- 55.77% 120.926% -- -- -27.65% 77.631%
Gross Income GR 3Y
-- -- 40.72% 127.338% -- -- -18.15% 90.490%
Operating Profit GR 3Y
-- -- 789.05% 94.645% -- -- -90.66% 10.646%
EBT GR 3Y
-- -- 284.98% 77.070% -- -- -80.38% 20.019%
Net Profit GR 3Y
-- -- -3.34% 67.581% -- -- -60.83% 69.915%
Net Profit Attributable To The Parent Company GR 3Y
-- -- -6.12% 63.206% -- -- -62.26% 67.329%
Total Assets GR 3Y
-- -- -8.51% 511.448% -- -- -12.97% 558.990%
Share Equity Without Minority Interest GR 3Y
-- -- -25.44% 629.637% -- -- -35.75% 844.479%
Equity GR 3Y
-- -- -24.86% 637.033% -- -- -35.68% 847.770%
Total Liabilities GR 3Y
-- -- 48.44% 349.468% -- -- 113.35% 235.424%
Basic Earning Per Share GR 3Y
-- -- -18.8% 19.466% -- -- -81.95% 23.972%
Net Assets Per Share GR 3Y
-- -- -- -46.443% -- -- -- --
Other Indicators
Currency Unit
HKDHKDHKDHKD

Q6, Q9, and FY are cumulative quarterly reports: Q6 is the interim report; Q9 is third quarter report; FY is the annual report.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Fonda Holdings is a contract research organization (CRO) that provides comprehensive and scientific research, analysis and development services to pharmaceutical companies throughout the drug discovery and development process. Its departments include North America and China. The North American division includes laboratory testing, chemistry, manufacturing and control (CMC), preclinical research and chemical services in the United States and Canada. The Chinese department includes laboratory testing, CMC, preclinical research, bioequivalent clinical and chemical services in China. Its preclinical studies include drug metabolism and pharmacokinetics (DMPK), safety, chemistry and toxicology, as well as laboratory tests, including bioanalysis and biological preparations, as well as central laboratories. Its services and solutions include candidate drug evaluation, product development, clinical services, and central laboratory and testing services.
CEO: Song Li
Market: Hong Kong motherboard
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...